Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Update

Aptevo Therapeutics Inc. (NASDAQ:APVO) was the target of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 241,700 shares, an increase of 536.1% from the November 30th total of 38,000 shares. Based on an average daily volume of 313,000 shares, the days-to-cover ratio is presently 0.8 days. Currently, 16.6% of the company’s shares are sold short.

Institutional Trading of Aptevo Therapeutics

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC purchased a new stake in Aptevo Therapeutics Inc. (NASDAQ:APVO) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned about 18.36% of Aptevo Therapeutics at the end of the most recent reporting period. 8.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Roth Mkm dropped their price objective on Aptevo Therapeutics from $20,535.00 to $10,952.00 and set a “buy” rating for the company in a research note on Monday, September 23rd. StockNews.com initiated coverage on shares of Aptevo Therapeutics in a research report on Monday, December 9th. They issued a “sell” rating for the company.

Aptevo Therapeutics Trading Down 8.8 %

Shares of APVO traded down $0.45 during mid-day trading on Friday, reaching $4.66. The company’s stock had a trading volume of 94,608 shares, compared to its average volume of 133,886. The company’s 50 day moving average is $247.83 and its 200 day moving average is $409.92. Aptevo Therapeutics has a 12-month low of $3.65 and a 12-month high of $399.60.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.